KCM
NBIX icon

Kornitzer Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Kornitzer Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,144
Closed -$4.25M – 476
2024
Q4 		$4.25M Hold
31,144
– – 0.08% 252
2024
Q3 		$3.59M Buy
+31,144
New +$4.27M 0.07% 266
2020
Q3 		– Sell
-121,751
Closed -$14.9M – 502
2020
Q2 		$14.9M Buy
+121,751
New +$13.5M 0.3% 124

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kornitzer Capital Management's NBIX Position: Q1 2025 in Review

Kornitzer Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 31,144 shares — an estimated $4.25M sold.

Kornitzer Capital Management first reported a position in NBIX in Q2 2020 and held it in 3 quarters. The position peaked at $14.9M in Q2 2020. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Kornitzer Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Kornitzer Capital Management sold 31,144 Neurocrine Biosciences shares in Q1 2025, an estimated $4.25M.
  • Kornitzer Capital Management first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 3 quarters.
  • Kornitzer Capital Management's Neurocrine Biosciences position peaked at $14.9M in Q2 2020.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Kornitzer Capital Management's 13F filing for Q1 2025, filed 2 May 2025.